Accuracy Coverage Pricing Help Centre Contact

BTG 2013 final results

Investment Tools Ltd.
BTG 2013 final results

Financial summary

Reported revenue including the impact of acquisitions was 24% higher at £290.5m (12/13: £233.7m); underlying1 revenue grew 20% to £244.8m (12/13: £203.8m)

Profit before tax 38% higher at £33.3m (12/13: £24.1m) reflects higher revenues and reduced impairment charges offset by increased investment in R&D and the Varithena launch

Basic EPS 36% higher at 6.8p (12/13: 5.0p)

Cash and equivalents of £38.2m at 31/3/14 (£158.7m at 31/3/13) post acquisitions and equity issue

Operating highlights Interventional Medicine

Revenue increased to £79.1m from £36.1m reflecting 16% growth in Beads and £45.0m new revenues from acquisitions

Varithena (polidocanol injectable foam) 1% approved in the US; controlled launch progressing well and first commercial treatments anticipated in Q3 2014

Acquisitions of TheraSphere® and EKOS Corporation completed; both businesses integrated and performing strongly in line with expectations

Increasing investment in R&D to accelerate TheraSphere® Phase III trials and deliver pipeline of product innovations for Beads, EKOS  and Varithena

Geographic expansion progressing: US sales force expanded; direct sales force being established in the EU, initially focusing on TheraSphere®; Asian hub established in Hong Kong

Specialty Pharmaceuticals

5% revenue growth to £102.3m in line with expectations following strong growth in prior period

Uridine triacetate progressing towards US New Drug Application; first EU named-patient sales made

Licensing

40% growth in underlying revenues to £109.1m driven by higher Zytiga® (abiraterone acetate) royalties

Lemtrada (alemtuzumab) approved in the EU for multiple sclerosis; US sBLA to be re-submitted

Louise Makin, BTG's CEO, commented: "2013/14 was a transformational year for BTG. With the approval of Varithena™ and the acquisitions of TheraSphere® and EKOS, we are now a leader in interventional medicine with vision to build a $1bn+ business by 2021. We have the resources and capabilities to invest in multiple growth opportunities to unlock the full value of our portfolio and pipeline, while in parallel seeking additional acquisition opportunities in both Interventional Medicine and Specialty Pharmaceuticals."

Companies mentioned

Latest News

Investment Tools Limited

The Smiths Group Board maintains a progressive dividend policy, aiming to increase dividends in line with long-term underlying growth in earnings and cash-flow. The policy enables them to retain sufficient cash-flow to finance investment in the drivers of growth and meet financial obligations. In setting the level of dividend payments, the Board considers prevailing economic conditions and future investment plans, along with the objective to maintain minimum dividend cover* of around 2 times.

Read more
Investment Tools Limited

The Hansard Board has proposed a final dividend of 2.65p per share, the same level as last year. In making this proposal, the Board has carefully considered its current financial position and future outcomes under a range of plausible adverse scenarios taking into account Covid-19.

Read more
Investment Tools Limited

The PZ Cussons Board is recommending a final dividend of 3.13p (2019: 5.61p) per share, making a total dividend for the year of 5.80p (2019: 8.28p) per share. The gross amount for the proposed final dividend is £13.1 million (2019: £23.5 million). 

Read more
Investment Tools Limited

On 2 April 2020 the board announced that it had decided to cancel the 2020 interim dividend, which would have been paid on 22 April 2020, recognising the significant challenges faced by businesses and individuals and consistent with the purpose of helping the people and businesses of Britain. 

Read more
Investment Tools Limited

The Alliance Pharma board have announced that, after suspending the final dividend payment for 2019 in response to the COVID-19 pandemic, it is declaring an interim dividend payment of 0.536p per share for 2020, in line with that for 2019. The Board will continue to assess the level of future cash distributions having regard to overall business performance and future outlook, in light of the global uncertainty created by COVID-19

Read more
Investment Tools Limited

The North American Income Trust revenue return per Ordinary share rose by 27.0% from 5.35p to 6.80p. The Board has declared a second quarterly dividend of 1.8p per share, giving total dividends for the first half of the year to 31 January 2021 of 3.6p (2020 - 3.4p), a 5.9% increase. The second quarterly dividend is payable on 30 October 2020 to shareholders on the register on 2 October 2020.

Read more
Investment Tools Limited

The Brooks Macdonald Board has recommended a final dividend of 32.0p (FY19: 32.0p) which, subject to approval by shareholders at the AGM, will result in total dividends for the year of 53.0p (FY19: 51.0p). This represents an increase of 3.9% on the previous year and reaffirms the Board's confidence in the strength of the business even in the context of the COVID-19 pandemic, and a commitment to a progressive dividend policy. The final dividend will be paid on 6 November 2020 to shareholders on the register at the close of business on 25 September 2020.

Read more
Investment Tools Limited

The Clinigen Directors are proposing to increase the final dividend to 5.46p per share (2019: 4.75p), resulting in a 14% increase in the full year dividend to 7.61p per share (2019: 6.7p).

Read more
Investment Tools Limited

The Hilton Food Directors have approved the payment of an interim dividend of 7.0p per share payable on 27 November 2020 to shareholders who are on the register at 30 October 2020. This interim dividend, amounting to £5.7m has not been recognised as a liability in these interim financial statements. It will be recognised in shareholders' equity in the 53 weeks to 3 January 2021.

Read more
Investment Tools Limited

The LXI Board has declared today an interim quarterly dividend in respect of the quarter ended 30 June 2020 of 1.30 pence per ordinary share, in line with the previous quarterly dividend guidance issued in May 2020. 

Read more
More News